当前位置：
X-MOL 学术
›
BMC Complement. Altern. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial.
BMC Complementary and Alternative Medicine ( IF 4.782 ) Pub Date : 2019-12-16 , DOI: 10.1186/s12906-019-2775-2 Shengyuan Yu 1 , Ye Ran 1 , Wei Xiao 2 , Wenjing Tang 1 , Jianjun Zhao 3 , Wei Chen 4 , Huikui Zhuang 5 , Cun Ouyang 6 , Hai Lin 7 , Dequan Liu 8 , Tongjun Chen 9 , Hui Huang 10 , Baoshen Wang 11 , Yanlei Hao 12 , Zhongrui Yan 13 , Shike Zhao 14 , Yanling Wang 15 , Jinjun Ni 16 , Chaodong Wang 17 , Wentao Ding 18 , Guoqian Li 19 , Jianhua Cao 20 , Shujuan Tian 21
BMC Complementary and Alternative Medicine ( IF 4.782 ) Pub Date : 2019-12-16 , DOI: 10.1186/s12906-019-2775-2 Shengyuan Yu 1 , Ye Ran 1 , Wei Xiao 2 , Wenjing Tang 1 , Jianjun Zhao 3 , Wei Chen 4 , Huikui Zhuang 5 , Cun Ouyang 6 , Hai Lin 7 , Dequan Liu 8 , Tongjun Chen 9 , Hui Huang 10 , Baoshen Wang 11 , Yanlei Hao 12 , Zhongrui Yan 13 , Shike Zhao 14 , Yanling Wang 15 , Jinjun Ni 16 , Chaodong Wang 17 , Wentao Ding 18 , Guoqian Li 19 , Jianhua Cao 20 , Shujuan Tian 21
Affiliation
BACKGROUND
Tianshu capsule (TSC), a formula of traditional Chinese medicine, has been widely used in clinical practice for prophylactic treatment of headaches in China. However, former clinical trials of TSC were small, and lack of a standard set of diagnostic criteria to enroll patients. The study was conducted to re-evaluate the efficacy and safety of TSC post-marketing in an extending number of migraineurs who have diagnosed migraine with the International Classification of Headache Disorders, 3rd edition (beta version, ICHD-3β).
METHODS
The study was a double-blind, randomized, placebo-controlled clinical trial that conducted at 20 clinical centers in China. At enrollment, patients between 18 and 65 years of age diagnosed with migraine were assigned to receive either TSC (4.08 g, three times daily) or a matched placebo according to a randomization protocol. The primary endpoint was a relative reduction of 50% or more in the frequency of headache attacks. The secondary outcomes included a reduction in the incidence of headache, the visual analogue scale of headache attacks, days of acute analgesic usage, and percentage of patients with a decrease of 50% or more in headache severity. Accompanying symptoms were also assessed.
RESULTS
One thousand migraine patients were initially enrolled in the study, and 919 of them completed the trial. Following the 12-week treatment, significant improvement was observed in the TSC group concerning both primary and secondary outcomes. After therapy discontinuation, the gap between the TSC group and the placebo group in efficacy outcomes continued to increase. There were no severe adverse effects.
CONCLUSIONS
TSC is an effective, well-tolerated medicine for prophylactic treatment of migraine, and still have prophylactic effect after medicine discontinuation.
TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT02035111; Data of registration: 2014-01-10.
更新日期：2019-12-16
京公网安备 11010802027423号